ForPatients
by Roche

Healthy Volunteers

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT02699372 2015-005509-35 BP30134

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, single center, adaptive single ascending dose (Part 1) and multiple ascending dose (Part 2) study is designed to assess the safety, tolerability, pharmacokinetic, and pharmacodynamics following an oral administration of RO6889450 versus placebo in healthy volunteers. The anticipated duration of this study is approximately 18 weeks.

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT02699372 2015-005509-35 BP30134
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 45 Years	Accepts Healthy Volunteers

© 2022 F. Hoffmann-La Roche Ltd